Sanofi and Orano Partner to advance next-gen radioligand medicines

Sanofi and Orano Med, which is a part of the Orano Group and specializes in targeted alphatherapies for cancer treatment, have agreed to collaborate in order to advance the development of advanced radioligand treatments for rare cancers. Sanofi...

Cullinan Therapeutics Receives US FDA Nod For phase 1 trial of CLN-978

Cullinan Therapeutics, Inc., a biopharmaceutical company specializing in developing targeted therapies, confirmed FDA approval for their Investigational New Drug Application for CLN-978. This enables the global phase 1 clinical trial in the US for...

Annovis Bio Receives US FDA Nod to begin phase 3 studies of buntanetap

Annovis Bio Inc, based in Malvern, a company in the advanced stages of clinical drug development, revealed on October 10, 2024, the positive results of their meeting with the US Food and Drug Administration regarding transformative treatments for...

Global CRDMO Work Distribution in India Expected to Rise up to 10% by 2033

The global CRDMO (Contract Research Development & Manufacturing Organisation) industry is about to witness a re-distribution of outsourcing work across several Asian countries, with India and Korea emerging as new powerhouses by 2033. At the...

Hoth Therapeutics Secures US patent for Alzheimer's treatment

Hoth Therapeutics, Inc., a company in the clinical stage of biopharmaceuticals that specializes in creating new treatments, is excited to share the news of receiving a US patent for their cutting-edge Alzheimer's treatment, HT-ALZ...

US FDA Nod GSK's Gepotidacin NDA for Treating Urinary Tract Infections

GSK plc reported that the NDA for gepotidacin, a new oral antibiotic for treating female adults and adolescents with uUTIs, has been accepted by the US FDA. The FDA has decided to give Priority Review to this application and has set a PDUFA action...

OKYO Pharma Announces Start of Phase 2 Trial For Neuropathic Corneal Pain

OKYO Pharma Limited, a company in the clinical stage of biopharmaceutical development, is creating new treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP). This billion-dollar market lacks FDA-approved therapy for...

Circle Pharma Declares First Patients Dosed in Phase 1 Clinical Trial

Circle Pharma, Inc., a company focused on finding and creating new macrocycle therapies, disclosed that the initial group of patients has been given doses in the phase 1 study of CID-078, their groundbreaking oral cyclin A/B RxL inhibitor...

Bayer Seeks EMA Approval for Elinzanetant to treat vasomotor symptoms

The biotechnology firm Bayer has requested approval from the European Medicines Agency (EMA) for elinzanetant to treat moderate to severe vasomotor symptoms (VMS, commonly known as hot flashes) linked to menopause or triggered by adjuvant...

Ampath and Innocent Hearts Hospital Partner to expand diagnostic services

American Institute of Pathology & Laboratory Sciences Pvt Ltd (Ampath) in collaboration with Innocent Hearts Superspeciality Hospital expands its diagnostic services in Jalandhar with the launch of a new state-of-the-art pathology laboratory...

© 2024 India Pharma Outlook. All Rights Reserved.